Ananya Ray Laskar, Anita S Acharya
Department of Community Medicine, Lady Hardinge Medical College,
New Delhi. India
Ananya Ray Laskar
A-601, Abhyant Apartments, Vasundhra Enclave, Delhi-110096. India.
Published Online -
Although adolescents constitute one-fifth of India's population, the National Immunisation Programme in our country primarily focuses on the under five children, with barely a provision of tetanus toxoid (TT) vaccine for adolescents. While Universal Immunisation Programme has resulted in the decline in incidence of vaccine preventable diseases among children, several unimmunised adolescents have become more susceptible to these diseases. Hence, there is an urgent need to take a re-look at the National Immunisation Schedule to incorporate vaccines for adolescents.
Vaccines may be categorised as routine, catch-up and optional vaccines according to the appropriateness and feasibility. Minor modifications such as TT vaccine may be replaced by Td for 10 and 16 years as part of routine immunisation. Hepatitis-B vaccine and Measles and Rubella vaccine may be given as catch-up vaccines. JE vaccine should be included for all adolescents in endemic states in view of the age shift in the incidence of the disease. More research and cost-effective analysis needs to be conducted for newer vaccines such as HPV and Hib. Effective planning of immunisation services for the adolescent will require careful weighing of the advantages and disadvantages of each individual vaccine. Resources need to be channelised to carry out the mammoth task of vaccinating the adolescents at the service delivery points keeping in mind the other issues of vaccine efficacy, cost, adverse events and maintenance of cold chain. Above all parents, service-providers, government as well as adolescents themselves have to be sensitised and made aware of vaccination for adolescents.
Adolescents; immunisation; vaccination; vaccines; India.
Vaccines: “With the exception of safe water, no other modality, not even antibiotics, has had such a major effect on mortality reduction …” 
India is a country of young. It is home to 243 million adolescents (10-19 years old) constituting 20% of the total population of India . Having the highest number of adolescents in the world– the key challenge that India faces, is ensuring the nutritional, health and educational needs of this population. Adequate immunisation of the adolescents would be one of the most cost-effective preventive health service and a vital health investment in this direction. Unfortunately, the National Immunisation Programme in our country has primarily focused on the under five children and pregnant women till now; tetanus toxoid being the only vaccine targeting the adolescent age group. There is also a dearth of research on this very relevant topic.
In India the vaccines recommended for adolescents are largely underused, due to lack of awareness and non-inclusion in the immunisation schedule, leaving our nation’s teens vulnerable to serious morbidity, and even death. Although Indian Academy of Pediatrics (IAP) guidelines do mention adolescent vaccination, health care providers are clueless due to its non-inclusion in the National Immunisation Schedule.
Need for sensitisation
Adolescent age-group presents special challenges for immunisation in relation to life-style and other social issues, whilst also offering special opportunities, such as vaccine delivery in the setting of educational institutions. Although many issues revolving around efficacy, safety and cost of introducing vaccines for adolescents at the national level are yet to be resolved, there is an urgent need to sensitise the policy makers as well as health care providers regarding this pertinent issue. A recently published 'National Vaccine Policy-2011' by Ministry of Health and Family Welfare, Government of India  gives guidelines to policy makers and programme managers regarding various strategies for strengthening Universal Immunisation Programme but the main focus is again on children and not the adolescents.
Vaccines recommended for use in adolescents can be grouped into broadly three categories:
1) Routine immunisation for all adolescents: The first aim is to increase the duration of effective protection derived from the vaccines already given earlier in life or 'booster effect', especially in the absence of primary immunisation. Many countries recommend the use of Td vaccines (containing adult type diphtheria toxoid) in adolescents.
2) “Catch-up” vaccines: which have been available for a longer time, are for administration to adolescents who were not immunised or were under-immunised as infants and toddlers. Disease control initiatives encompass immunising across a wide age range, with the aim of increasing herd immunity, interrupting transmission or catching-up on cohorts missed in the past. For instance, measles elimination in certain countries has targeted individuals from 9 months to 14 years.
3) Optional vaccines: Vaccines which may be given to a particular vulnerable group depending upon the risk-factor but need not be made mandatory in the National Immunisation schedule; such as Haemophilus influenzae (Hib) and Human Papilloma virus (HPV) vaccines. Special efforts may be appropriate to immunise them before they enter the risk period.
Individual Vaccines and recommendations
Diphtheria, Pertussis and Tetanus (DPT):
Diphtheria- The duration of immunity against diphtheria may depend on exposure to diphtheria organisms and thus varies geographically. Data on the persistence of immunity in developing countries like India are scarce. But even where vaccination coverage rates have been high for 5 to 10 years, diphtheria outbreaks have been reported. These are characterised by high case fatality rates, a large proportion of patients with complications, and occurrence in both younger and older age groups . Epidemics in previously well-controlled settings in Eastern Europe have raised awareness of the need for wider vaccination strategies. Though there is a dearth of studies reporting the actual disease burden of diphtheria in adolescents and adults, several outbreaks have been reported in India [5-9] which points towards waning immunity beyond childhood.
Pertussis- Although the majority of adolescents have received one or more doses of DPT in infancy, there is evidence that protective immunity to pertussis may wane . The duration of immunity following DPT immunisation is not precisely known. Epidemiological investigations with whole-cell pertussis vaccine suggest that the efficacy of the vaccine falls with time after immunisation . An increasing incidence of pertussis cases among adolescents and adults in developed countries may reflect decreasing levels of immunity in these groups. Some serological observations suggest that past infection may not provide protection and that the widely held belief that infection with B. pertussis confers lifelong immunity is probably wrong .
Tetanus- National Immunisation Schedule has already targeted adolescents of 10 and 16 years as well as pregnant women to receive tetanus toxoid (TT). As discussed above, TT should be replaced by Td in all states that have had DPT-3 coverage of 70% or more for at least 5 years as per WHO .
Recommendations: According to the 2012 guidelines given by the Advisory Committee on Immunisation Practices (ACIP) of CDC, adolescents aged 11 through 18 years who have not received Tdap vaccine should receive a dose, followed by tetanus and diphtheria toxoids (Td) booster doses every 10 years thereafter . However due to the cost factor, it is not feasible to adapt this guideline in the Indian scenario. The latest National Immunisation Schedule of India recommends that DPT vaccine can be given up to 7 years of age, but no specific changes in recommendations are suggested for adolescents .
For those who can afford the vaccine, the preferred age for TdaP is 11-12 years. Lower dose of the diphtheria component of the vaccine , (recommended for persons over the age of 7 years) are advised to minimise adverse reactions . Recent field trials conducted in Italy, Sweden, and Germany indicate that 'acellular’ pertussis vaccines cause significantly lower rates of reactions than whole cell pertussis vaccines, and also that acellular vaccines are 70%-90% effective in preventing severe pertussis cases . However considering the cost of acellular pertussis vaccine, only Td vaccine may be feasible for adolescents at 10 and 16 years as nation-wide guideline. School-based programmes for administering booster doses of Td may be the best strategy to cover the gaps in immunity.
Measles, Mumps and Rubella (MMR):
Measles- Single dose of measles vaccine given at 9 months is effective in protecting 85% of infants vaccinated. Rationale for second dose is to achieve levels of protection (>92%) where reduction in transmission is achieved; further the second dose addresses the 15% non-responders at first immunisation. Overall, based on these well established scientific facts, changing from one dose to two dose strategy would help catch up those missed but more importantly elevate the level of immunity to break transmission of disease. Even in a developed country like USA where first dose of measles vaccine is given as a part of MMR vaccine at 12-15 months, a second dose of measles vaccine is recommended at 4-6 years, to overcome initial vaccine failures which form a small fraction of vaccines, as well as to boost the falling titres of protective antibodies over a period of time .
Rubella is a benign disease of childhood but has serious teratogenic effects in the baby in the form of Congenital Rubella Syndrome. The rate of perinatal transmission is 40-50% overall and 90% during the first trimester of pregnancy. As about 40% women in reproductive age group in India are susceptible to rubella, vaccination against this is desirable in adolescent girls . A community based study by All India Institute of Medical Sciences, India in unmarried adolescent girls reported high seronegativity indicating high susceptibility to rubella infections . It has been seen that inadequate coverage may decrease rubella virus circulation in children sufficiently with the resultant upward shift of the median page at infection; thus leading to higher proportion of girls remaining susceptible up to adulthood leading to a paradoxical increase in the number of rubella infections and of cases of Congenital Rubella Syndrome . Therefore introduction of rubella vaccine for adolescent girls is recommended to offset the potential of increase of susceptible women in reproductive age group, if children alone are vaccinated.
Mumps does not pose a significant public health problem in children as it is uncommon in children less than 12 months of age and has negligible mortality. Mumps is similar to measles but less transmissible in household setting and has lower crude herd immunity. However some complications are known to occur if the disease occurs after puberty. Orchitis occurs in 37% of the post-pubertal males after mumps while 31% of the affected females have mastitis and pelvic pain due to oophoritis. Also an increase in foetal deaths has been observed in women who develop mumps in the first trimester .
Recommendations: A one-time measles “catch-up” campaign targeting children 9 months to 14 years of age may be carried out at national level to immunise susceptible, accumulated since vaccine introduction . Among the neighbouring countries, Sri Lanka, Bhutan, Maldives and Thailand have already introduced MR/MMR in their national immunisation programme. National Technical Advisory group has proposed the introduction of rubella vaccine as MR/MMR in the Universal Immunisation Programme in states which have the ability to achieve and sustain routine immunisation coverage of >80% . This would also provide a second opportunity for measles vaccination. Specific choice of MR/MMR should be made on the basis of incremental cost between the two . Thus all adolescents in the country should be immunised regardless of their measles vaccination status.
Hepatitis B vaccine
It can be used effectively through routine infant immunisation, but is effective at any age though less after the age of 40 years. If given prior to exposure, it can prevent infection in almost all individuals, and will reduce dramatically rates of liver cancer later in life [21,22]. Most persons infected with hepatitis B virus (HBV) acquire their infection as young adults or adolescents. Any reduction in HBV- related liver disease resulting from universal vaccination of infants cannot be expected until vaccinated children reach adolescence and adulthood . In 2002, Government of India had launched Hepatitis-B immunisation as part of routine immunisation in 33 districts and 15 metropolitan cities with Global Alliance for Vaccine and Immunisation (GAVI) support  and recently it is proposed to be expanded to the whole country . However given that the majority of today’s adolescents will not have received this vaccine in infancy, a short-term programme of immunisation for adolescents may also be indicated as a catch-up strategy .
Recommendations: A schedule of 0, 1-2, and 4-6 months is recommended. Flexibility in scheduling is an important factor for achieving high rates of vaccination in adolescents. When the vaccination schedule is interrupted, the vaccine series does not require re-initiation . Studies of "off-schedule" vaccinations indicate that if the series is interrupted after the first dose, the second dose should be administered as soon as possible, and the second and third doses should be separated by an interval of at least 2 months. If only the third dose is delayed, it should be administered as soon as possible. Intervals of up to 1 year between administration of the first and third doses induce excellent antibody responses, and studies are in progress to evaluate longer intervals .
As per IAP recommendations there are certain special conditions that warrant special mention to administer the vaccine to high risk adolescents . These are health workers, travellers to endemic countries, intravenous drug users, males having sex with men, an intimate contact with HBs antigen positive patients, patients regularly receiving blood or haemodialysis.
Japanese Encephalitis (JE):
It is the leading viral cause of Acute Encephalitis Syndrome (AES) in India. 70% of those who develop illness either die or survive with a long-term neurological disability. Government of India made the decision to control JE by introducing a mass vaccination programme in 104 endemic districts in 11 states of India in a phased manner for 5 years from 2006-2011 by using the live attenuated SA 14-14-2 JE vaccine manufactured in Chengdu Institute of Biological Products, China . Since the disease primarily affects children under the age of fifteen years, a one-time JE massimmunisation campaign targeting all the children in the 1-15 years age group in the high-risk districts was also started. Some districts of Manipur, Nagaland, Arunachal Pradesh and Uttarakhand showing evidence of ongoing JE transmission were also included in 2010 . A recently conducted hospital-based study among AES patients in Assam reported 259 (47.1%) serologically confirmed cases as JE, of which 66.4% were adult and 33.6% were paediatric. This age shift may be due to the invasion of the disease into new demography or some change in the virus strain over time . The Assam Government has initiated a pilot project to expand JE vaccination in adults in the worst-hit districts of Assam from October 2011.
Recommendations for use of JE vaccines:
Currently the vaccine has been integrated into the Universal Immunisation for children 16-24 months in all the endemic states in India . In view of the age-shift in the incidence of the disease, JE vaccination should be recommended across all agegroups including adolescents in endemic areas, as part of national immunisation.
Haemophilus influenza vaccine:
The H. influenzae pitman type b (Hib) organism, which can cause severe bacterial meningitis and pneumonia, is estimated to kill more than 370,000 children worldwide each year. Nearly 20% of these deaths occur in India. Preliminary data from six surveillance centres indicates case fatality rate of Hib meningitis is 25%, 76% cases occur in infants and 40-50% of isolates are resistant to first-line antibiotics. Clinical trials of Hib conjugate vaccines have demonstrated that this vaccine can prevent 20-25% radiologically confirmed pneumonia with consolidation . However there is dearth of studies to estimate the burden of disease in adolescents.
A study conducted in the Department of Child Health, CMC Vellore  reported that even at relatively low coverage through private sector distribution, Hib vaccine has significant community impact on Hib disease. The annual mean number of Hib cases was 10.7 before Hib vaccine introduction, falling to 3.8 cases following its Recommendations: The risk of disease in adolescents is extremely low and thus routine immunisation is not indicated for healthy individuals above 5 years as per IAP guidelines .
However, in some special conditions like chronic respiratory diseases- asthma, immunocompromised adolescents like splenectomised or post-bone marrow transplant patients a single dose 0.5 ml by intramuscular route may be administered annually .
It is another common disease and is mild with low mortality if occurs in childhood. Primary varicella has a mortality rate of 2-3 per 100,000 cases with lowest case fatality rates among children aged 1-4 years and 5-9 years. Most children are infected by age of 15 years with fewer than 5% adults remaining susceptible. Disease is often severe if it occurs after adolescence or in adults. Natural infection provides lifelong immunity .
Recommendations: Varicella vaccine is not recommended for children in routine immunisation schedule. At ages 11–12 years, providers should assess the adolescent’s need for varicella virus vaccine, and administer the vaccine to those who are eligible and do not have a reliable history of chickenpox. When administered to children <13 years of age, a single dose of vaccine induces protective antibodies in >95% of recipients. For susceptible persons 13 years and above, two doses separated by 4–8 weeks are recommended. But the vaccine is costly as it costs about Rs.1200 per dose.
Therefore, in case of financial constraints parents may be given the option to get their child immunised if they can afford it . Moreover varicella vaccine should not be given to adolescents who are known to be pregnant or to adolescents who are planning pregnancy within 1 month of vaccination. However the vaccine must be recommended to household contacts of immuno-compromised children or health care workers in ‘Infectious disease hospitals’.
Invasive meningococcal disease is most common in children with rates of more than 25/1,00,000 population in the first four months of life. Almost 50% cases occur in children less than 2 years of age. Meningococcal vaccine is a polysaccharide vaccine effective against meningococcemia as well as N. meningitidis meningitis which have a high mortality rate. However, being a polysaccharide vaccine it is poorly immunogenic in children less than two years of age, though its protein conjugate variant has been shown to be efficacious .
Recommendations: Currently a quadrivalent vaccine is available (against A, C, Y and W135 strains). As one dose of vaccine provides protection for 3-5 years and repeated doses result in hyporesponse, meningococcal vaccine is recommended for prevention among the close contacts and for control of epidemics and not as a part of routine immunisation .
Human Papilloma Virus (HPV) Vaccines Cervical cancer is the most common cancer in women in India. HPV infections are very common among sexually transmitted infections and the lifetime risk of acquired HPV infection is 70–80% in many developing countries . With the advent of two new vaccines, one quadrivalent vaccine “Gardasil” ® (against HPV-6, -11, -16, and -18) developed by Merck and one bivalent “Cervarix” ® (against HPV-16, and -18) by GSK , may hold newer promises for prevention and control of the disease. However, a word of caution that vaccination alone does not prevent all cervical cancers. Nearly 30% of cancers are not prevented by the currently available vaccines .
Therefore, age-appropriate screening programmes for cervical cancer should go hand in hand. Also, the cost of this vaccine is a major factor along with other issues such as public awareness and acceptability of the vaccine. Many conservative elements of the society have expressed their concern that it might encourage promiscuity among unmarried. Also there is a question of whether to offer it to boys. Hence, various regulatory and policy changes along with awareness among parents may need to be undertaken to address these issues.
Recommendations: The primary target population should be young adolescent girls as vaccination is most efficacious in girls who have not become sexually active. So, the programmes should determine the primary target age group based on data on the age of sexual initiation and the feasibility of reaching young adolescent girls through schools, health-care facilities or community-based methods . The vaccine manufacturers recommend three doses of the vaccine to be administered to females aged 10-26 years. CDC recommends either HPV4 or HPV2 for females and HPV4 for males aged 11 or 12 years in a 3-dose series. The vaccine series can be started beginning at age 9 years. The second dose to be administered 1 to 2 months after the first dose and the third dose 6 months after the first dose . But each dose cost about Rs. 3000/- and hence is not recommended as part of routine immunisation in adolescents . However, it can be made optional for those who can afford them. In addition, screening at regular intervals after initiation of sexual activity cannot be over-emphasised along with creating public awareness regarding cervical cancer and HPV vaccine.
So, currently, only a few vaccines fulfill the criteria for widespread use in adolescents. A summary of the IAP and the recommendations for the National Immunisation for adolescents have been presented in table 1.
Table 1- Recommendations for adolescent immunisation
Barriers to adolescent vaccination may be of three types- Beneficiary or family-related, provider related or system-related.
i) Beneficiary related barriers: Changing behaviour among adolescents and their parents or guardians will require education and outreach. While younger children have little or no control over health care decisions, adolescents often play a key role in decision making. Therefore, it is vital that adolescents, as well as their parents, are educated about the need for vaccinating the adolescents and the seriousness of vaccine-preventable diseases. Once empowered, they may generate discussion with their health care providers about vaccines and other preventive health measures.
ii) Provider related barriers: Vaccine delivery strategies may be school-based programmes, pulsed delivery through child health days, vaccination days, periodic campaigns, routine provision through health facilities, or combination of strategies can be adopted. Further seroepidemiological studies are needed to be carried out to know the epidemiological patterns and burden of vaccine preventable diseases among adolescents in India. The already existing mechanism for routine immunisation can be utilised optimally by appropriate training and sensitisation.
iii) System related barriers: The choice of which vaccine to give, target population among the adolescent age group and mode of administration are important policy decisions that must be guided by a strong scientific rationale, with rigorous inputs from multicentric field epidemiology, irrespective of policies in western countries. Cost-benefit as well as risk-benefit assessment of vaccinating adolescents should be carried out in India, taking into account local serotypes and variations in indigenous host - pathogen - environment interactions. The public sector undertakings manufacturing indigenous vaccines should be revived and upgraded .
Effective planning of immunisation services for the adolescent will require careful weighing of the advantages and disadvantages of each individual vaccine by the policy makers. Currently, only a few vaccines fulfill the criteria for widespread use in adolescents. In the future, we might even have a vaccine against HIV/AIDS to be used in adolescents and many more. So the need of the hour is health promotional messages for the adolescents and their families to convince them that the recommended vaccines are safe and effective and relevant for themselves.
- Guidelines for the adolescent vaccination should be incorporated in the National Immunisation Schedule and widely disseminated.
- A modification such as replacement of TT vaccine with Td (adult type) is recommended for 10 and 16 years.
- Hepatitis-B vaccine and MR vaccine may be given as catch-up vaccines. In addition, JE vaccine should be included for all adolescents in endemic states in view of the age shift in the incidence.
- Plotkin SL, Plotkin SA A short history ofvaccination. In: Plotkin SA, Orenstein WA, Offit PA (eds). Vaccines. Saunders, Philadelphia, 2008,5th ed; 1-16.
- Global strategies, policies and practices for immunisation of adolescents, A review, Department of Vaccines and Biologicals and Department of Child and Adolescent health and Development, WHO Geneva 1999 http://www.indianpediatrics.net/mar2004/m ar-239-244.htm Accessed on 30-08-2011.
- National Vaccine Policy http://mohfw.nic.in/WriteReadData/l892s/10 84811197 National Vaccine Policy Book.pdf Accessed on 30-08-2011.
- CDC. Preventing Tetanus, Diphtheria, and Pertussis among Adolescents: Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccines. MMWR Morb Mortal Wkly Rep 2006;55:1-34.[PUBMED]
- Bitragunta S, Murhekar MV, Hutin YJ, Penumur PP, Gupte MD. Persistence of diphtheria, Hyderabad, India, 2006. Emerg Infect Dis 2008;14:1144-6.[PUBMED]
- Sharma NC, Banavaliker JN, Ranjan R, Kumar R.Bacteriological and epidemiological characteristics of diphtheria cases in and around Delhi - A retrospective study. Indian J Med Res 2007;126:545-52.[PUBMED]
- Nath B, Mahanta TG. Investigation of an outbreak in Borborooah block of Dibrugarh district, Assam. Indian J Community Med 2010;35:436-8.[PUBMED]
- Dravid MN, Joshi SA. Resurgence of diphtheria in Malegaon and Dhule regions of north Maharashtra. Indian J Med Res 2008;127:616-7.[PUBMED]
- Murhekar MV, Bitragunta S. Persistence of Diphtheria in India. Indian J Community Med 2011;36:164-5.[PUBMED]
- Recommended immunisation schedules for persons aged 0 through 18 years- United States, 2010. CDC MMWR, 2010; 58 (51&52):1-4.[PUBMED]
- Tan T, Trindade E, Skowronski D. Epidemiology of Pertussis. Pediatr Infect Dis J 2005;24:S10-18.[PUBMED]
- Advisory Committee on Immunization Practices. Recommended Adult Immunization Schedule: United States 2012. Ann Intern Med 2012;156:211-7.[PUBMED]
- Immunisation Handbook for Health Workers. Ministry of Health and Family Welfare, Govt of India. 2011:13-15.
- Indian Academy of Pediatrics Guidebook on Immunisation, IAP Immunisation Committee. Yewale V, Choudhary P, Thacker N (eds). Indian Academy of Pediatrics. Mumbai, 2011:145-53.
- Crowcroft NS, Pebody RG. Recent Developments in pertussis. Lancet 2006;367:1926-36.[PUBMED]
- CDC Measles, mumps, and rubella – vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunisation Practices. MMWR Morb Mortal Wkly Rep 2011;47(RR-8):1-5.
- Bhaskaram P, Ramalakshmi BA, Raju LA, Raman L. Need for protection against rubella in India. Indian J Pediatr 1991;58:811-4.[PUBMED]
- Rustgi R, Deka D, Singh S. Rubella serology in Indian adolescent girls and its relation to socioeconomic status. J Obstet Gynecol India 2005;55:167-9.
- Plotkin S, Rubin SA. Mumps vaccine. In: Plotkin S, Orenstein W, Offit P (eds) Vaccines, Saunders, Philadelphia 2008, 5th edn:435-66.
- Madhavi Y, Puliyel JM, Mathew JL, Raghuram N, Phadke A, Shiva M, et al. Evidence-based National Vaccine Policy. Indian J Med Res 2010; 131:617-28.[PUBMED]
- Chowdhury A, Santra A, Pal S, Chakravarty R, Banerji A, Pal S, et al. Community based epidemiological study of Hepatitis B virus infection (HBV). Indian J Gastroenterol 2001:20(Suppl 2); A2.
- Tandon BN, Acharya SK, Tandon A. Epidemiology of Hepatitis B virus infection in India. Gut 1996;389(suppl 2):S56-S59.[PUBMED]
- Aggarwal R, Ghoshal UC, Naik SR. Assessment of cost-effectiveness of universal hepatitis B immunisation in a low income country with intermediate endemicity using a Markov model. J Hepatol 2003;38:215-22.[PUBMED]
- Proposal for introduction of Hepatitis-B vaccine in the Universal Immunisation Programme in better performing states. Global Alliance for Vaccine and Immunisation. Revision 5 February 2005. www.gavialliance.org/.../proposals/proposal-for-nvs---hep-b-support... Accessed on 22-09-11.
- Operational Guide for Japanese B Encephalitis Vaccination in India. Immunisation Division, Department of Family Welfare, Ministry of Health and Family Welfare, Government of India. September 2010 : 15 . http://health.bih.nic.in/Docs/Guidelines- Japanese-Encephalitis.pdf Accessed on 22-09- 11.
- Borah J, Dutta P, Khan SA, Mahanta J. A comparison of clinical features of Japanese encephalitis virus infection in the adult and ediatric age group with Acute Encephalitis Syndrome. J Clin Virol 2011;52:45-9.[PUBMED]
- Levine OS, Wenger JD. Defining the burden of the disease in India. Indian Pediatr 2002;39:5-11.[PUBMED]
- Verghese VP, Friberg IK, Cherian T, Raghupathy P, Balaji V, Lalitha MK, et al. Community effect of Hemophilus Influenzae type B vaccination in children. Pediatr Infect Dis J 2009; 28:738-40.[PUBMED]
- Taneja DK, Sharma P. Newer vaccines- need for informed choice. Indian J Community Med 2006;31:53-5.
- Martin MG, Seward JF, LaRussa PS. Viral Infections- Varicella Zoster virus. In: Kliegran RM, Behrman RE, Jenson HB, Stanton BF (eds). elson Textbook of Pediatrics, Saunders, Philadelphia, 2008, 18th edn:1366-71.
- Orenstien W, Pickering LK. Immunization Practices. In: Kliegran RM, Behrman RE, Jenson HB, Stanton BF (eds) Nelson Textbook of Pediatrics, Saunders, Philadelphia, 2008, 18th edn:1058-69.
- CDC. Updated recommendations for use of meningococcal conjugate vaccines- Advisory Committee on Immunisation Practices (ACIP), MMWR Morb Mortal Wkly Rep 2011;60:72-6.[PUBMED]
- Bhatla N, Joseph E. Cervical cancer prevention and the role of Human Papillomavirus Vaccines in India. Indian J Med Res 2009;130:334-40.[PUBMED]
- Laskar AR, Garg S, Sodhani P. Cervical cancer vaccine: Exploring new opportunities and challenges for developing countries. Ann Trop Med Public Health 2011;4:54-6.
- Karande S. Update on available vaccines in India: Report of Asia Pacific Pediatric Association Vaccinology Update 2010. Ind J Pediatr 2011;78:845-53.[PUBMED]